Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CXCR3 | P49682 | 10/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22763936 | 1.00 | TSHR (0.34) | TSHRMEN1KMT2AADRB2LMNA | |
| SCHEMBL22764034 | 0.84 | TSHR (0.38) | TSHRMEN1KMT2ALMNAMAPK1 | |
| SCHEMBL1205580 | 0.79 | NFKB1 (0.41) | TSHRMEN1KMT2AADRB2LMNA | |
| SCHEMBL828863 | 0.79 | ADRB2 (0.38) | ADRB2 | |
| SCHEMBL17651818 | 0.79 | ADRB2 (0.38) | TSHRADRB2 | |
| SCHEMBL1204929 | 0.79 | NFKB1 (0.41) | TSHRMEN1KMT2AADRB2LMNA | |
| SCHEMBL2012341 | 0.79 | NFKB1 (0.41) | TSHRMEN1KMT2AADRB2LMNA | |
| SCHEMBL2569901 | 0.79 | ADRB2 (0.38) | ADRB2 | |
| SCHEMBL9574119 | 0.77 | ADRB2 (0.36) | ADRB2 | |
| SCHEMBL25214019 | 0.76 | ALDH1A1 (0.46) | MEN1KMT2AADRB2LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053227-B2 | Process for preparing intermediates for the synthesis of optically active beta-amino alcohols by enzymatic reduction and novel synthesis intermediates | OLON S.P.A. (IT) | 2021-07-06 | — | — | US | disclosed |
| US-20200385366-A1 | PROCESS FOR PREPARING INTERMEDIATES FOR THE SYNTHESIS OF OPTICALLY ACTIVE BETA-AMINO ALCOHOLS BY ENZYMATIC REDUCTION AND NOVEL SYNTHESIS INTERMEDIATES | OLON S.P.A. (IT) | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385366-A1 | PROCESS FOR PREPARING INTERMEDIATES FOR THE SYNTHESIS OF OPTICALLY ACTIVE BETA-AMINO ALCOHOLS BY ENZYMATIC REDUCTION AND NOVEL SYNTHESIS INTERMEDIATES | ADH1A, ADH1C, ADH5 | TSHR 3858/4885MEN1 2751/4885KMT2A 1774/4885 |
| US-11053227-B2 | Process for preparing intermediates for the synthesis of optically active beta-amino alcohols by enzymatic reduction and novel synthesis intermediates | ADH1A, ADH1C, ADH5 | TSHR 3858/4885MEN1 2751/4885KMT2A 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.